APHA Stock Forecast: Aphria Inc plummets as cannabis sector gets hammered
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ:APHA drops by 6.70% as the broader markets experience a small correction on Thursday.
- Aphria and Tilray both crash as the cannabis heavyweights prepare for their impending merger.
- Analysts side with Aphria as Tillray continues to get downgrades from Wall Street.
NASDAQ:APHA has had a stellar 2021 so far like much of the cannabis industry has, but that came to a screeching halt on Thursday as the broader markets hit a minor speed bump. Aphria’s stock fell by 6.70% and closed the bumpy trading session at $19.23, which is still well above its 50-day and 200-day moving averages. The Ontario, Canada-based company has rewarded its investors so far this year returning over 160% even though the stock has fallen since peaking at a 52-week high of $32.29 earlier this month.
Much of the talk around Aphria this year has revolved around its impending merger with Tilray (NASDAQ:TLRY), one of the leaders of the Canadian cannabis industry. Tilray surprised Wall Street and investors this past week with a better than expected earnings report which included strong fourth-quarter revenues and steadily growing margins. Despite this, several analysts still downgraded Tilray for the long-run, citing that the Nanaimo-based firm may not be strong enough to stand on its own for much longer. The merger with Aphria seems to be happening at just the right time for Tilray, which also saw its stock fall by 14% on Thursday.
APHA stock price
Aphria CEO Irwin Simon will be running the new merger which will still operate under the Aphria brand. Both companies will look to leverage each other as they plan to expand operations into Europe’s medicinal marijuana market once the deal is settled. At this point, with European countries already legalizing cannabis for medical use, the continent may be a more profitable point of entry as the United States still awaits federal legalization. Besides, there are already plenty of American cannabis companies in operation for when that legislation inevitably occurs.
- NASDAQ:APHA drops by 6.70% as the broader markets experience a small correction on Thursday.
- Aphria and Tilray both crash as the cannabis heavyweights prepare for their impending merger.
- Analysts side with Aphria as Tillray continues to get downgrades from Wall Street.
NASDAQ:APHA has had a stellar 2021 so far like much of the cannabis industry has, but that came to a screeching halt on Thursday as the broader markets hit a minor speed bump. Aphria’s stock fell by 6.70% and closed the bumpy trading session at $19.23, which is still well above its 50-day and 200-day moving averages. The Ontario, Canada-based company has rewarded its investors so far this year returning over 160% even though the stock has fallen since peaking at a 52-week high of $32.29 earlier this month.
Much of the talk around Aphria this year has revolved around its impending merger with Tilray (NASDAQ:TLRY), one of the leaders of the Canadian cannabis industry. Tilray surprised Wall Street and investors this past week with a better than expected earnings report which included strong fourth-quarter revenues and steadily growing margins. Despite this, several analysts still downgraded Tilray for the long-run, citing that the Nanaimo-based firm may not be strong enough to stand on its own for much longer. The merger with Aphria seems to be happening at just the right time for Tilray, which also saw its stock fall by 14% on Thursday.
APHA stock price
Aphria CEO Irwin Simon will be running the new merger which will still operate under the Aphria brand. Both companies will look to leverage each other as they plan to expand operations into Europe’s medicinal marijuana market once the deal is settled. At this point, with European countries already legalizing cannabis for medical use, the continent may be a more profitable point of entry as the United States still awaits federal legalization. Besides, there are already plenty of American cannabis companies in operation for when that legislation inevitably occurs.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.